hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06378346 id: 2023-077 briefTitle: GU-01: Glycyrrhizin in Prostate Cancer acronym: GU-01 overallStatus: RECRUITING date: 2024-05 date: 2026-03 date: 2026-03 date: 2024-04-22 date: 2024-04-26 name: University of Illinois at Chicago class: OTHER briefSummary: This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy) conditions: Prostate Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Glycyrrhizin name: Glycyrrhizin name: Observation measure: Number of participants that have a change in prostate-specific antigen (PSA) before GLY administration measure: Number of participants that have a change in prostate-specific antigen (PSA) after GLY administration and prior to radical prostatectomy measure: The tolerability of GLY will be assessed by NCI Common Terminology Criteria for Adverse Events (AE) (NCI CTCAE) Version 5 (v5.0). measure: Assessment of plasma GLY levels after GLY administration measure: Assessment of blood sodium levels after GLY administration measure: Assessment of blood potassium after GLY administration measure: Assessment of serum creatinine after GLY administration measure: Assessment of serum testosterone levels after GLY administration measure: Assessment of serum dehydroepiandrosterone sulfate (DHEA-S) levels after GLY administration measure: Assessment of interleukin-1β (IL-1β) after GLY administration measure: Assessment of Tumor necrosis factor α (TNFα) after GLY administration measure: Assessment of interleukin 6 (IL-6) after GLY administration measure: Assessment of serum Vascular Endothelial Growth Factor (VEGF) after GLY administration measure: Assessment of Hepatocyte Growth Factor (HGF) after GLY measure: Assessment of Insulin-like Growth Factor-1 (IGF-1) after GLY measure: Evaluate patient perspectives on clinical trial enrollment and complementary and integrative medicine (CAM) approaches as evaluated through survey questionnaires administered before GLY administration measure: Evaluate patient perspectives on clinical trial enrollment and complementary and integrative medicine (CAM) approaches as evaluated through survey questionnaires administered after GLY administration measure: Gene expression analysis in tumor specimens obtained before administration of GLY measure: Number of patients with changes in gene expression analysis in tumor specimens obtained after administration of GLY sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Illinois status: RECRUITING city: Chicago state: Illinois zip: 60612 country: United States name: Natalie Reizine, MD role: CONTACT phone: 312-996-1581 email: nreizi2@uic.edu name: Omer Qazi, MBBS role: CONTACT phone: 312-413-1069 email: omerqazi@uic.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06378333 id: 2024-01-023 briefTitle: Incidence, Clinical Characteristics and Outcomes of Unstable Angina in the contempoRary Area. acronym: ICAR overallStatus: COMPLETED date: 2022-11-27 date: 2024-01-27 date: 2024-04-15 date: 2024-04-22 date: 2024-04-22 name: University Hospital, Montpellier class: OTHER briefSummary: The study aims to evaluate clinical characteristics and prognostic of a contemporary population of patients with UA defined using T hs-cTn measurements The study includes all patients admitted in 2 French university centers with the confirmed diagnostic of UA defined with clinical ischemic symptoms and T hs-cTn concentrations \< 99 percentile (undetectable: \<5ng/l or non-elevated: \<14ng/l), or ≥ 99 percentile but mildly elevated (14-50ng/l) .The primary end-point included major events at 1-year follow-up (total mortality, new ACS, hospitalization for cardiac causes). conditions: Unstable Angina studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 210 type: ACTUAL name: patients who underwent coronary angiography measure: Hospitalisation for of unstable Angina sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital of Montpellier city: Montpellier zip: 34295 country: France lat: 43.61092 lon: 3.87723 hasResults: False
nctId: NCT06378320 id: STUDY20240287 briefTitle: eHealth for Breastfeeding Support - the HOTSPOT Trial overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-01 date: 2025-06-01 date: 2024-04-22 date: 2024-04-22 name: University Hospitals Cleveland Medical Center class: OTHER briefSummary: This is a voluntary research study to test use of a phone app that is intended to support breastfeeding specifically for African American and Black people. This is called a "pilot" study because the app is still in development. The goal of this research is to see if mothers use the app more when they receive text "nudges" to look at it compared to not getting those "nudges". The research project is being conducted by Lydia Furman MD.
Up to 24 participants will be enrolled at UHCMC, including up to 20 mothers. Other participants will include up to 4 African American or Black fathers/partners whose partners are interested in breastfeeding. conditions: Breast Feeding studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This will be a prospective randomized two arm study for expectant women and a prospective randomized two arm study for fathers/partners. All participants receive access to the wireframe app. Maternal participants will be randomized to nudge or no nudge via text with those in the app "nudge" group receiving questions weekly prior to delivery and biweekly (every 2 weeks) after delivery through 3 months postpartum. The purpose of these "nudges" is to assess whether participants are more likely to access and benefit from the app if they are encouraged to explore it. Father/partner participants will also be randomized to either a nudge or no nudge group with those in the "nudge" group receiving questions weekly for the first two months and then biweekly (every 2 weeks) for another two months. primaryPurpose: OTHER masking: NONE count: 24 type: ESTIMATED name: App access and Text message name: App access only measure: Maternal participants app usability score measure: Father/partner participants app usability score measure: Maternal participants app engagement score measure: Father/partner participants app engagement score measure: Maternal participants breastfeeding knowledge at enrollment measure: Maternal participants breastfeeding knowledge after app exposure measure: Father/partner participants breastfeeding knowledge at enrollment measure: Father/partner participants breastfeeding knowledge after app exposure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ahuja Rainbow Center for Women and Children city: Cleveland state: Ohio zip: 44103 country: United States lat: 41.4995 lon: -81.69541 facility: Passages, Inc. city: Cleveland state: Ohio zip: 44103 country: United States name: Lydia Furman MD role: CONTACT phone: 216-675-6691 email: lydia.furman@uhhospitals.org lat: 41.4995 lon: -81.69541 facility: University Hospital MacDonald Women's Hospital city: Cleveland state: Ohio zip: 44106 country: United States lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06378307 id: CHUBX2022-06 briefTitle: A Transferability Study on the Conditions for a Successful Inclusive Education acronym: TIAP overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-06-30 date: 2025-06-30 date: 2024-04-22 date: 2024-04-22 name: University Hospital, Bordeaux class: OTHER briefSummary: The investigators are conducting a realist evaluation study with a multi-case and qualitative design. The study aims to identify the conditions that promote successful students with disabilities inclusive education at school. This study is nested in the TIAP research (Research to explore the conditions transfer of innovations in the field of disability, with a view to developing a transfer framework). conditions: Inclusive Education studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 114 type: ESTIMATED measure: Effect of inclusive education on children with disabilities autonomy and social participation at school measure: Effect of inclusive education on children with disabilities autonomy and social participation in their proximal living environment (leisures participation) measure: Effect of inclusive education on social participation of families with children with disabilities sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06378294 id: UHACoruna briefTitle: Locoregional Control With Radiotherapy of Breast Cancer Patients With MACrometastases Treated With MAstectomy (MACMA) acronym: MACMA overallStatus: RECRUITING date: 2021-04-20 date: 2024-12-31 date: 2029-12-31 date: 2024-04-22 date: 2024-04-25 name: University Hospital A Coruña class: OTHER name: Complejo Hospitalario Universitario de Pontevedra name: Complejo Hospitalario Universitario de Vigo name: Complejo Hospitalario Universitario de Santiago name: Hospital Universitario Lucus Augusti name: Complexo Hospitalario de Ourense briefSummary: Sentinel lymph node biopsy (SLNB) is the standard procedure to stage the axilla in clinically node-negative invasive breast cancer (IBC) patients undergoing upfront surgery.
The ACOSOG-Z0011 and the AMAROS trial demonstrated that SLNB with or without radiotherapy provided equivalent local control and survival to axillary lymph node dissection (ALND) in early-stage breast cancer patients with 1 or 2 positive SLNs. However, the ACOSOG-Z0011 trial did not included patients treated with mastectomy, and the AMAROS trial only included 17% of mastectomy patients.
The investigators conduct an observational cohort study of early stage breast cancer patients receiving upfront mastectomy with 1 or 2 macrometastases after SLNB. The study aim to demonstrate a 5-year disease-free survival of not less than 80% when ALND is omitted and replaced by axillary radiotherapy, and determine the axillary recurrence rate. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Mastectomy measure: Disease-free survival measure: Axillary recurrence rate measure: Overall survival sex: FEMALE minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitario Ferrol status: RECRUITING city: Ferrol state: A Coruña zip: 15402 country: Spain name: EULALIA VIVES role: CONTACT email: Eulalia.Vives.Rodriguez@sergas.es name: EULALIA VIVES role: PRINCIPAL_INVESTIGATOR name: MANUEL DÍAZ role: SUB_INVESTIGATOR lat: 43.4896 lon: -8.21942 facility: Hospital Universitario Santiago de Compostela status: RECRUITING city: Santiago De Compostela state: A Coruña zip: 15706 country: Spain name: MARÍA EFIGENIA ARIAS role: CONTACT email: efi.arias@yahoo.com name: MARÍA EFIGENIA ARIAS role: PRINCIPAL_INVESTIGATOR lat: 42.88052 lon: -8.54569 facility: Hospital Universitario Vigo status: RECRUITING city: Vigo state: Pontevedra zip: 36214 country: Spain name: GONZALO DE CASTRO role: CONTACT email: gonzalo.jose.de.castro.parga@sergas.es name: GONZALO DE CASTRO role: PRINCIPAL_INVESTIGATOR name: GEORGINA FREIRÍA role: SUB_INVESTIGATOR lat: 42.23282 lon: -8.72264 facility: Hospital Universitario A Coruña status: RECRUITING city: A Coruña zip: 15006 country: Spain name: ALBERTO BOUZÓN role: CONTACT phone: +34690103810 email: dr.alberto@aecirujanos.es name: BENIGNO ACEA role: CONTACT phone: +34650482409 email: benigno.acea.nebril@sergas.es name: MARÍA ALEJANDRA GARCÍA role: SUB_INVESTIGATOR name: ALBERTO BOUZÓN role: PRINCIPAL_INVESTIGATOR name: BENIGNO ACEA role: PRINCIPAL_INVESTIGATOR lat: 43.37135 lon: -8.396 facility: Hospital Universitario Lugo status: RECRUITING city: Lugo zip: 27003 country: Spain name: LAURA MUÍÑOS role: CONTACT email: laura.muiños.ruano@sergas.es name: LAURA MUÍÑOS role: PRINCIPAL_INVESTIGATOR name: PATRICIA VÁZQUEZ role: SUB_INVESTIGATOR lat: 43.00992 lon: -7.55602 facility: Hospital Universitario Ourense status: RECRUITING city: Orense zip: 32005 country: Spain name: MANUEL GARCÍA role: CONTACT email: Manuel.Garcia.Garcia2@sergas.es name: MANUEL GARCÍA role: PRINCIPAL_INVESTIGATOR lat: 42.33669 lon: -7.86407 facility: Hospital Universitario Pontevedra status: RECRUITING city: Pontevedra zip: 36071 country: Spain name: MARÍA TERESA FERNÁNDEZ role: CONTACT email: terefez@yahoo.es name: MARÍA TERESA FERNÁNDEZ role: PRINCIPAL_INVESTIGATOR lat: 42.431 lon: -8.64435 hasResults: False
nctId: NCT06378281 id: CRSK-3_221381 briefTitle: Testing a New Method to Improve Informed Consent in Prison Research acronym: Spark BATIR overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-04-30 date: 2025-09-30 date: 2024-04-22 date: 2024-04-24 name: Stéphanie Baggio class: OTHER name: University of Bern name: Leiden University name: School of Health Sciences Fribourg name: University Hospital, Geneva briefSummary: Understanding of informed consent is often limited in prison, due to unique challenges faced by detained people. This study will test a modified "teach-to-goal" informed consent process compared to standard procedures. Conducted within a larger study on psychiatric outcomes, it aims to enhance ethical practices for vulnerable populations. conditions: ADHD studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Modified teach-to-goal informed consent measure: Understanding of the informed consent (binary) measure: Understanding of the informed consent (continuous) measure: Evaluation of the informed consent sex: MALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Geneva University Hospitals city: Geneva zip: 1211 country: Switzerland name: Stéphanie Baggio, Prof. role: CONTACT phone: +41316846774 email: stephanie.baggio@unibe.ch lat: 46.20222 lon: 6.14569 hasResults: False
nctId: NCT06378268 id: 05/24/DD-BVMD briefTitle: PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study) acronym: ProGanOS overallStatus: RECRUITING date: 2024-04-24 date: 2025-12-31 date: 2026-09-30 date: 2024-04-22 date: 2024-04-26 name: Mỹ Đức Hospital class: OTHER briefSummary: This non-inferiority randomized controlled trial will be conducted at My Duc Hospital, Ho Chi Minh City, Vietnam.
This study compares the effectiveness of Progestin-Primed Ovarian stimulation versus GnRH protocol for ovarian stimulation in IVF treatment. Participants will be randomly assigned in a 1:1 ratio to receive Progestins or GnRH antagonists. conditions: Progestins Primed Ovarian Stimulation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 626 type: ESTIMATED name: Dydrogesterone 10 mg name: Cetrorelix 0.25 mg measure: Ongoing pregnancy measure: The incidence of premature LH surge measure: The incidence of premature progesterone elevation measure: Number of oocytes retrieved measure: Number of mature oocytes measure: Number of day 3 embryos measure: Number of day 5 embryos measure: Number of good quality day 3 embryos measure: Number of good quality day 5 embryos measure: Number of frozen embryos measure: Incidence of Ovarian hyperstimulation syndrome measure: Positive ß-hCG test measure: Clinical pregnancy measure: Ectopic pregnancy measure: Early miscarriage <12 weeks measure: Late miscariage 12-< 22 weeks measure: Live birth rate measure: Gestational age at birth measure: Mode of delivery measure: Birth weight measure: Very low birth weight measure: Low birth weight measure: High birth weight measure: Very high birth weight measure: Preterm birth measure: Gestational diabetes mellitus measure: Hypertensive disorders of pregnancy measure: Maternal mortality measure: Major congenital abnormalities measure: NICU admission measure: Reason for NICU admission measure: Neonatal mortality sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: My Duc Hospital status: RECRUITING city: Ho Chi Minh City zip: 70000 country: Vietnam name: Tuong M Ho, MD role: CONTACT phone: +84 90 3633377 email: tuongho.ivfmd@gmail.com lat: 10.82302 lon: 106.62965 hasResults: False
nctId: NCT06378255 id: PKUSSNCT-23A04 id: PKUSSIRB-202393160 type: OTHER domain: Ethics Committee of PKUSH of Stomatology id: Z221100007422088 type: OTHER_GRANT domain: The SFP for clinical CDTT in capital briefTitle: Clinical Evaluation of Polycation-based New Dental Desensitizer on Dentin Hypersensitivity overallStatus: RECRUITING date: 2024-03-20 date: 2025-06-30 date: 2025-09-01 date: 2024-04-22 date: 2024-04-22 name: Peking University Hospital of Stomatology class: OTHER briefSummary: Evaluate the safety and clinical efficacy of new dental desensitizers in the treatment of dentin sensitivity, including the relief of sensitivity symptoms and the duration of efficacy. conditions: Dentin Sensitivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Polycation-based new dentinal desensitizer name: GLUMA desensitizer measure: Improvement of dentin sensitivity induced by probe pressure stimulation measure: Improvement of dentin sensitivity induced by air temperature stimulation sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University School and Hospital of Stomatology status: RECRUITING city: Beijing state: Beijing zip: 100081 country: China name: Qianqian Wang role: CONTACT phone: +86-10-62173403 email: wangqian0213@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06378242 id: RC48-C029 briefTitle: To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 overallStatus: NOT_YET_RECRUITING date: 2024-04-23 date: 2029-03-15 date: 2029-12-31 date: 2024-04-22 date: 2024-04-22 name: RemeGen Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2 conditions: High-risk Non-muscle Invasive Bladder Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Disitamab Vedotin for injection measure: Incidence of dose-limiting toxicity(DLT) (Phase I) measure: Incidence of Adverse event (Phase I) measure: Recommended Phase II Dose(RP2D) measure: Maximum Tolerated Dosage(MTD) measure: Disease-free survival (DFS) rates measure: Duration of response (DOR) measure: Disitamab Vedotin anti-drug antibody (ADA) measure: PK of enfortumab vedotin: Maximum concentration (Cmax) measure: PK of enfortumab vedotin: Trough concentration (Ctrough) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen Memorial Hospital,SunYat-sen University city: Guangzhou state: Guangdong country: China name: Tianxin Lin, Ph.D role: CONTACT lat: 23.11667 lon: 113.25 facility: Hunan Cancer hospital city: Changsha state: Hunan country: China name: Shusuan Jiang, M.D role: CONTACT lat: 28.19874 lon: 112.97087 facility: The first affiliated hospital with nanjing medical universtity city: Nanjing state: Jiangsu country: China name: qiang Lv, M.D role: CONTACT lat: 32.06167 lon: 118.77778 facility: Shandong Cancer hospital & Institute city: Jinan state: Shangdong country: China name: Jiasheng Bian, M.D role: CONTACT name: Yuping Sun role: SUB_INVESTIGATOR lat: 36.66833 lon: 116.99722 facility: The first affiliated hospital withXi'an Jiao Tong Universtity city: Xi'an state: Shanxi country: China name: Lei Li, M.D role: CONTACT lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06378229 id: ONZ-2023-0157 id: 2022-501857-35-00 type: CTIS briefTitle: Psilocybin for Hospitalized Patients With Treatment-resistant Depression acronym: PSIHOS-D overallStatus: RECRUITING date: 2024-04 date: 2026-03 date: 2026-12-31 date: 2024-04-22 date: 2024-04-25 name: University Hospital, Ghent class: OTHER name: Filament Health briefSummary: The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression. conditions: Treatment Resistant Depression studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Open label feasibility study primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Psilocybin measure: Incidence and type of Treatment-Emergent Adverse Events measure: Columbia-Suicide Severity Rating Scale (C-SSRS) measure: Recruitment and retention rates. measure: Qualitative data from the semi-structured interviews with the subjects and their partners. measure: Montgomery Asberg Depression Rating Scale (MADRS) measure: Quick Inventory of Depressive Symptomatology - Self Rated (QIDS-SR) measure: State-Trait Anxiety Inventory (STAI) measure: World Health Organization Quality of Life Inventory-Brief subscale (WHOQOL-BREF) measure: Maudsley 3-item Visual Analogue Scale (M3VAS) measure: Subjective Emotional Health Visual Analogue Scale (SEHVAS) measure: revised Dyadic Adjustment Scale (RDAS) measure: Zarit Burden Interview - Short Form (Zarit-12 Burden Scale) measure: Client Experiencing Scale (EXP) measure: Mystical Experience Questionnaire (MEQ) measure: Working Alliance Inventory - Short Revised (WAI-SR) measure: Semi-structured interviews. measure: EEG: sensor level analysis (power) and source level analysis (functional connectivity through amplitude envelope correlation), both in resting state and during an emotional paradigm. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ghent University Hospital status: RECRUITING city: Gent state: Oost-Vlaanderen zip: 9000 country: Belgium name: Cisse Geleyn, dr. role: CONTACT phone: +3293328742 email: cisse.geleyn@uzgent.be name: Gilbert Lemmens, prof. dr. role: PRINCIPAL_INVESTIGATOR lat: 51.05 lon: 3.71667 hasResults: False
nctId: NCT06378216 id: MEDEA 975 briefTitle: Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe] acronym: MDCJ-NeuBeRe overallStatus: RECRUITING date: 2022-09-15 date: 2024-03-18 date: 2024-12-30 date: 2024-04-22 date: 2024-04-22 name: IRCCS Eugenio Medea class: OTHER briefSummary: The rationale of the study is to collect structured data in the neuropsychological, clinical neuroradiologic and neurorehabilitation fields in children/young people affected by congenital and juvenile myotonic dystrophy. Children affected by the congenital form (CDM1) present important brain alterations present since birth while, on the contrary, patients with the adult form of DM1 often present a degenerative, slowly progressive neurocognitive picture. Promising therapies that aim to correct the molecular mechanism underlying the symptoms of adult forms of DM1 are under development, but their potential role at the level of the nervous system and in particular in forms of CDM1 (which appears to be a distinct disorder of neuronal development) is also to be clarified.